Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 465

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 465
---
 that will be granted to the lenders upon conversion of the loan into shares. The non -marketablewarrants will be issued at a rate equal to 125% of the total loan conversion shares outstanding at the effective time of conversion. The exercise price of the warrants will be equal to a rate of 110% of the conversion share price, and the exercise period will be 42months from the date of their issuance; (J)Adjustment for $860,433 related to conversion of loan from related parties as noted above at closing of merger; (J)Adjustment for $1,511,653 related to conversion of loans from related parties as noted above at closing of merger; (J)Adjustment for $5,060,872 related to conversion of convertible loan and warrants as noted above at closing of merger; (J)Adjustment to remove $5,043,768 of interest expense related to loans converted as noted above at closing as if merger took place January1, 2024, for the twelve months ended December31, 2024; (K)Adjustment to record elimination of $1,238,425 of share premium and $62,560,326 ordinary shares of Kadimastem, no par value, at the Closing; (L)Adjustments to reflect the modified par value of $2,796,062 for NLS Preferred Shares and $61,927 for NLS Common Shares as approved on January14, 2025 by the shareholders of NLS from CHF 0.80 to CHF 0.03 per share, effective January17, 2025; (M)Elimination of NLS accumulated deficit of $73,880,474 and accumulated other comprehensive loss of $108,853 at closing of merger; (N)Adjustment of $1,108,387 to record issuance of 33,535,661 NLS Common Shares to Kadimastem at CHF 0.03 par value upon closing of the merger to currently represent 80% currently estimated ownership in NLS; (O)To reflect the preliminary allocation in the unaudited pro forma condensed combined financial statements, management has estimated the purchase price allocation based on currently available information. The carrying value of NLS’s net assets is assumed to approximate fair value, and the excess of the purchase consideration over the estimated fair value of those net assets has been preliminarily allocated to intangible assets — specifically, in -processresearch and development (IPR&D) — and goodwill